Zhi Tong Cai Jing·2026-02-06 12:52Core Viewpoint - China Resources Pharmaceutical (03320) reported preliminary unaudited financial data for Tianjin Tasly Pharmaceutical (600535) for the year ending December 31, 2025, indicating a decline in total operating revenue while showing an increase in net profit attributable to shareholders [1] Financial Performance - Total operating revenue for Tianjin Tasly Pharmaceutical reached RMB 8.236 billion, representing a year-on-year decrease of 3.08% [1] - Net profit attributable to shareholders amounted to RMB 1.105 billion, reflecting a year-on-year increase of 15.68% [1] Revenue Breakdown - The decline in operating revenue is primarily attributed to a 14.24% decrease in pharmaceutical commercial revenue, mainly from the chain pharmacy business, influenced by industry policies such as "outpatient overall planning" [1]